August 19, 2014 — PALO ALTO, Calif., Aug. 19, 2014 — Cellular Research announced today the start of an early access program for its Precise™ assays and is currently making the product available to 10 sites.

The Precise assays provide ultra-sensitive RNASeq assay technology designed to examine large numbers of standard or low input mRNA samples in high throughput. Based on Cellular Research’s Molecular Indexing™ technology, the assays provide the highest accuracy and precision available and are designed for rare and precious samples or whenever absolute quantitation is required. The Precise assays combine molecular and sample indexing in 96 and 384 sample formats, enabling customers to sequence up to 2,000 samples on one sequencing run without investment in new equipment or extensive training. The assays deliver unprecedented accuracy and sensitivity for low expression targets in rare and low quantity samples. Combined with robust design and data analysis pipelines the assays deliver a simple turnkey solution for targeted RNASeq experiments. Early access customers may start with a list of genes in which they are interested, and Cellular Research will generate the specific panel of assays for them.

Several high profile research and commercial customers have validated the assays and additional interested users should contact Cellular Research. Data from the early access program will be used to further validate the performance of the assays and optimize assay design and experimental analysis.

The Precise assays the next in a series of products developed by Cellular Research and represent a key step in our goal of enabling high throughput and high resolution genomics, said Steve Fodor Ph.D., Chief Executive Officer of Cellular Research.
These assays are highly reproducible, and we are using our unique Molecular Indexing technology to allow precise quantitation of each mRNA transcript, Fodor concluded.

In conjunction with the Precise assay, Cellular Research is collaborating with Seven Bridges Genomics (SBG) to offer customers a complete analysis pipeline, which provides an integrated cloud-based data platform for management, execution and collaboration of the RNASeq experiments in a robust, easy-to-use informatics platform.

The Seven Bridges Genomics (SBG) Platform provides an integrated cloud computing environment to manage, execute and collaborate on all aspects of NGS analysis workflows. SBG is proud to work with Cellular Research to provide their customers with a robust and easy to use workflow which meets CR’s specifications and executes on the Seven Bridges Platform, said CEO Deniz Kural.